Challenges and opportunities when using oral chemotherapy in the home setting: The example of capecitabine (Xeloda®)

European Journal of Oncology Nursing

Volumn 8, Issue SUPPL. 1, 2004, Pages

  Molassiotis, Alexander ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CENTER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; EDITORIAL; HAND FOOT SYNDROME; HOME CARE; HUMAN; MEDICAL EDUCATION; METASTASIS; OUTPATIENT; PATIENT CARE; PATIENT EDUCATION; PRIMARY MEDICAL CARE;

EID: 4444225701     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejon.2004.06.004     Document Type: Editorial

References (21)

1. B. Ardalan M.R. Flores A new complication of chemotherapy administered via permanent indwelling central venous catheter Cancer 75 8 1995 2165-2168
2. A. Birner Pharmacology of oral chemotherapy agents Clinical Journal of Oncology Nursing 7 Suppl. 6 2003 11-19
3. T.R. Buroker M.J. O'Connell H.S. Wieand J.E. Krook J.B. Gerstner J.A. Mailliard P.L. Schaefer R. Levitt C.G. Kardinal D.H. Gesme Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer Journal of Clinical Oncology 12 1 1994 14-20
4. J. Cassidy C. Twelves E. van Cutsem P. Hoff E. Bajetta M. Boyer R. Bugat U. Burger A. Garin U. Graeven J. McKendrick J. Maroun J. Marshall B. Osterwalder G. Pérez-manga R. Rosso P. Rougier R.L. Schilsky on behalf of the Capecitabine Colorectal Cancer Study Group First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin Annals of Oncology 13 2002 566-575
5. Cassidy J. Scheithauer W. McKendrick J. Kröning H. Nowacki M.P. Seitz J.F. Twelves C. Van Hazel G. Wong A. Díaz-Rubio E. On Behalf Of X-act Study Investigators 2004 Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial Proceedings of the American Society of Clinical Oncology (abstract 3509)
6. I. Chau S. Legge P. Fumoleau The vital role of education and information in patients receiving capecitabine (Xeloda®) European Journal of Oncology Nursing 8 Suppl. 1 2004 S41-S53
7. S. Faithfull P. Deery Implementation of capecitabine (Xeloda®) into a cancer centre UK experience European Journal of Oncology Nursing 8 Suppl. 1 2004 S54-S62
8. C. Ferlini I. Ojima M. Distefano M. Gallo A. Riva P. Morazzoni E. Bombardelli S. Mancuso G. Scambia Second generation taxanes: from the natural framework to the challenge of drug resistance Current Medical Chemotherapy Anti-Cancer Agents 3 2 2003 133-138
9. B.-M. Gerbrecht T. Kangas Implications of capecitabine (Xeloda®) for cancer nursing practice European Journal of Oncology Nursing 8 Suppl. 1 2004 S63-S71
10. R. James C. Blanco C. Farina Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer European Journal of Cancer Supplements 1 5 2003 S83 (abstract 271)
11. A. Jucgla G. Sais Diagnosis in oncology: HFS Journal of Clinical Oncology 15 9 1997 3164
12. Y. Lassere P. Hoff Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®) European Journal of Oncology Nursing 8 Suppl. 1 2004 S31-S40
13. H. Marsé E. Van Cutsem A. Grothey S. Valverde Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) European Journal of Oncology Nursing 8 Suppl. 1 2004 S16-S30
14. M. Miwa M. Ura M. Nishida N. Sawada T. Ishikawa K. Mori N. Shimma I. Umeda H. Ishitsuka Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue European Journal of Cancer 34 8 1998 1274-1281
15. V.J. O'Neill C.J. Twelves Oral cancer treatment: developments in chemotherapy and beyond British Journal of Cancer 87 2002 933-937
16. H.-J. Schmoll Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents European Journal of Cancer 32A Suppl. 5 1996 S18-S22
17. J. SchÜller J. Cassidy E. Dumont B. Roos S. Durston L. Banken M. Utoh K. Mori E. Weidekamm B. Reigner Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemotherapy and Pharmacology 45 2000 291-297
18. C.N. Sternberg P. Reichardt M. Holland Development of and clinical experience with capecitabine (Xeloda®) in the treatment of solid tumours European Journal of Oncology Nursing 8 Suppl. 1 2004 S4-S15
19. C. Twelves M. Boyer M. Findlay J. Cassidy C. Weitzel C. Barker B. Osterwalder C. Jamieson K. Hieke on behalf of the Xeloda Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma European Journal of Cancer 37 2001 597-604
20. E. Van Cutsem P.M. Hoff P. Harper R.M. Bukowski D. Cunningham P. Dufour U. Graeven J. Lokich S. Madajewicz J.A. Maroun J.L. Marshall J.L. Mitchell G. Perez-Manga P. Rougier W. Schmiegel J. Schoelmerich A. Sobrero A. Schilsky Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials British Journal of Cancer 90 2004 1190-1197
21. M. Verso G. Agnelli Venous thromboembolism associated with long-term use of central venous catheters in cancer patients Journal of Clinical Oncology 21 19 2003 3665-3675